Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis.

Masahiro Toda Yoshiharu Yamanobe Masato FujiokaYukina MorimotoMariko FukumuraMasato NakayaYumiko OishiMizuto SatoRyo UedaHirokazu FujiwaraTetsuro HikichiShinobu Noji Naoki OishiHiroyuki OzawaKaoru OgawaYutaka KawakamiTakayuki OhiraKazunari YoshidaMasahiro Toda

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

This study demonstrated the safety and preliminary efficacy of VEGFR peptide vaccination in patients with NF2. Memory-induced CTLs after VEGFR vaccination may persistently suppress tumor progression.

Keyphrases

vascular endothelial growth factor
signaling pathway
oxidative stress
lps induced
endothelial cells
pi k akt
working memory
immune response
inflammatory response
cell proliferation
drug induced
long non coding rna
stress induced